-
公开(公告)号：US20240009238A1
公开(公告)日：2024-01-11
申请号：US18044955
申请日：2021-09-14
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Joycelyn WÜSTEHUBE-LAUSCH , Hans-Ulrich SCHMOLDT
IPC: A61K35/17 , C07K16/28 , C12N5/0783 , A61K39/00 , A61P35/00
CPC classification number: A61K35/17 , C07K16/28 , C12N5/0636 , A61K39/4633 , A61K39/4611 , A61P35/00 , A61K39/464402 , A61K2239/13
Abstract: The invention relates to agents and methods for targeted delivery of payloads to cells. The agents and methods are useful for delivering therapeutic or diagnostic agents to target cells. In one embodiment, the invention involves administering RNA encoding a peptide or polypeptide (docketing compound) comprising a binding moiety (primary targeting moiety) binding to target cells and a further binding moiety (secondary target) binding to an agent that comprises a payload (effector probe). Following expression of the RNA, the primary targeting moiety may bind to a target antigen such as a cancer antigen on cancer cells and then a secondary targeting moiety comprised in the effector probe may target the secondary target to thereby precisely deliver a “payload” to the target cells such as cancer cells.
-
公开(公告)号：US20230295335A1
公开(公告)日：2023-09-21
申请号：US18184120
申请日：2023-03-15
Applicant: Genmab A/S , BioNTech SE
Inventor： Andreea IOAN , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , David P.E. SATIJN , Ugur SAHIN , Alexander MUIK , Kristina SCHÖDEL , Sina FELLERMEIER-KOPF , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/30 , C07K16/2878 , C07K2317/31 , C07K2317/92
Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
-
公开(公告)号：US20220257631A1
公开(公告)日：2022-08-18
申请号：US17595587
申请日：2020-05-20
Applicant: BIONTECH SE , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Inventor： Ugur SAHIN , David WEBER , Carina WALTER , Diana BAREA ROLDAN , Ruprecht KUNER , Meike WAGNER , Martin SUCHAN , Stefania GANGI MAURICI , Stefanie HUBICH-RAU , René BECKER
IPC: A61K31/7088 , A61P35/00 , A61K9/00
Abstract: Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof, or an immunogenic fragment of the CLDN6 or the immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic variant thereof, or an immunogenic fragment of the p53 or the immunogenic variant thereof; and (iii) an amino acid sequence comprising Preferentially Expressed Antigen In Melanoma (PRAME), an immunogenic variant thereof, or an immunogenic fragment of the PRAME or the immunogenic variant thereof.
-
公开(公告)号：US20220143144A1
公开(公告)日：2022-05-12
申请号：US17442568
申请日：2020-04-02
Applicant: BIONTECH SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Inventor： Ugur SAHIN , Mathias VORMEHR , Lena KRANZ , Sina FELLERMEIER-KOPF , Alexander MUIK , Daniel REIDENBACH , Mustafa DIKEN , Sebastian KREITER
Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.
-
公开(公告)号：US20220064317A1
公开(公告)日：2022-03-03
申请号：US17360437
申请日：2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
Patent Agency Ranking
公开(公告)号：US20250009780A1
公开(公告)日：2025-01-09
申请号：US18578844
申请日：2022-07-13
Applicant: BIONTECH SE
Inventor： Ugur SAHIN , Christiane STADLER , Claudia LINDEMANN , Ursula ELLINGHAUS , Hayat BÄHR-MAHMUD , Leyla FISCHER , Anuhar CHATURVEDI , Gábor BOROS , Jonas REINHOLZ , Sergey BESSONOV , Katalin KARIKÓ
Abstract: The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.
-
公开(公告)号：US20250002600A1
公开(公告)日：2025-01-02
申请号：US18696689
申请日：2022-10-05
Applicant: Genmab A/S , BioNTech SE
Inventor： Alexander MUIK , Kristina SCHÖDEL , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN , Sina FELLERMEIER-KOPF , Patricia GARRIDO CASTRO , Jordan BLUM , Friederike GIESEKE , Esther C. W. BREIJ , Lars GUELEN , Joost NEIJSSEN , Karsten BECKMANN , Claudia PAULMANN , Bart-Jan DE KREUK , Richard G. HIBBERT , Janine SCHUURMAN , Aran LABRIJN , Ivan KUZMANOV
Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
28.发明公开公开(公告)号：US20230399403A1
公开(公告)日：2023-12-14
申请号：US18035172
申请日：2021-11-11
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Karsten BECKMANN , Claudia PAULMANN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Alexander MUIK , Ivan KUZMANOV
IPC: C07K16/28 , G01N33/574
CPC classification number: C07K16/2818 , G01N33/57492 , C07K2317/565 , G01N2333/70521 , C07K2317/92 , C07K2317/76 , C07K2317/24
Abstract: The present disclosure relates to antibodies having the ability of binding to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody having the ability of binding to the immune checkpoint protein PD-1, such as human PD-1, or a nucleic acid encoding such an antibody, or a composition comprising said antibody or nucleic acid.
-
公开(公告)号：US20230089969A1
公开(公告)日：2023-03-23
申请号：US17817033
申请日：2022-08-03
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20230087745A1
公开(公告)日：2023-03-23
申请号：US17821837
申请日：2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.015 seconds)
